The Australian subsidiary of CSL Behring is set to develop a plasma-derived therapeutic for the treatment of serious complications in Covid-19 patients.
The company intends to focus on patients whose infection is progressing to the requirement for ventilation.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Named Covid-19 Immunoglobulin, the therapeutic will be developed by CSL Behring Australia at its manufacturing facility in Broadmeadows, Victoria.
